{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:13:26Z","timestamp":1786374806556,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.2459\/jcm.0b013e32832edac0","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:53:57Z","timestamp":1283331237000},"page":"616-623","source":"Crossref","is-referenced-by-count":19,"title":["Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors"],"prefix":"10.2459","volume":"10","author":[{"given":"Jan","family":"Steffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210207","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","article-title":"Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications","volume":"113","author":"Steffel","year":"2006","journal-title":"Circulation"},{"key":"R2-5-20210207","first-page":"337","article-title":"Novel anticoagulants: confused at a higher level?","volume":"11","author":"Steffel","year":"2008","journal-title":"Kardiovaskul\u00e4re Medizin"},{"key":"R3-5-20210207","first-page":"10","article-title":"Oral anticoagulation: practical considerations for the practicing clinician","volume":"6","author":"Steffel","year":"2007","journal-title":"Cardiovasc"},{"key":"R4-5-20210207","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"R5-5-20210207","doi-asserted-by":"crossref","first-page":"110S","DOI":"10.1378\/chest.08-0652","article-title":"Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"R6-5-20210207","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/vhrm.2006.2.4.371","article-title":"Fondaparinux in the management of patients with ST-elevation acute myocardial infarction","volume":"2","author":"Turpie","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"R7-5-20210207","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"R8-5-20210207","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"R9-5-20210207","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-5-20210207","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"R11-5-20210207","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1160\/TH07-06-0394","article-title":"Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism","volume":"98","author":"Shetty","year":"2007","journal-title":"Thromb Haemost"},{"key":"R12-5-20210207","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-5-20210207","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"R14-5-20210207","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.17.5.773","article-title":"Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders","volume":"17","author":"Prandoni","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R15-5-20210207","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/ATVBAHA.108.162677","article-title":"New anticoagulants for treatment of venous thromboembolism","volume":"28","author":"Gross","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-5-20210207","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-5-20210207","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-5-20210207","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"R19-5-20210207","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R20-5-20210207","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-5-20210207","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"R22-5-20210207","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-5-20210207","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"R24-5-20210207","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"R25-5-20210207","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"R26-5-20210207","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R28-5-20210207","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R29-5-20210207","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.106.653428","article-title":"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial","volume":"115","author":"Cohen","year":"2007","journal-title":"Circulation"},{"key":"R30-5-20210207","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2003-12-4195","article-title":"New anticoagulants","volume":"105","author":"Hirsh","year":"2005","journal-title":"Blood"},{"key":"R31-5-20210207","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"R32-5-20210207","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R33-5-20210207","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R34-5-20210207","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R35-5-20210207","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-5-20210207","first-page":"611","article-title":"The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results","volume":"15","author":"Mahaffey","year":"2003","journal-title":"J Invasive Cardiol"},{"key":"R37-5-20210207","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial","volume":"83","author":"Koster","year":"2007","journal-title":"Annals Thorac Surg"},{"key":"R38-5-20210207","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"R39-5-20210207","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R40-5-20210207","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01244665-200908000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:17:31Z","timestamp":1786371451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01244665-200908000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0b013e32832edac0","relation":{},"ISSN":["1558-2027"],"issn-type":[{"value":"1558-2027","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}